BeyondSpring Reports $50.5 Million Q3 Net Income, Advances DUBLIN-4
BeyondSpring (BYSI) reported Q3 2026 net income of $50.5M, driven by a $53.7M gain from selling subsidiary interests, while continuing operations had a $2.1M net loss. The company had no revenue and a $2.1M operating loss. FDA granted Fast Track designation to Plinabulin plus docetaxel for NSCLC treatment. BeyondSpring sold its stake in Bulin to Biolin, which will support China-based enrollment in the DUBLIN-4 trial.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data on cash position and pipeline progress, offering traders a basis for short‑term positioning.
Market read
Primary earnings disclosure for a micro‑cap biotech; modest impact expected pending market reaction to operating loss versus one‑time gain.
What to watch
Potential future revenue from the DUBLIN‑4 trial in China and FDA Fast Track status could unlock upside not reflected in the short‑term price.
Background
BeyondSpring Inc. (BYSI) filed an 8‑K reporting Q3 2026 results, a $53.7M sale of a subsidiary, and FDA Fast Track designation for its Plinabulin combination therapy.
Ticker impact
BeyondSpring reported Q3 2026 net income of $50.5M, driven by a $53.7M gain on the sale of subsidiary interests and a $2.1M operating loss from continuing operations.
mixed, potential downside as operating loss offsets gain from asset sale
The gain is a one‑time item; investors may discount it, focusing on the continuing loss, which could pressure the stock.
Market effects
Biotech sector may see modest attention due to FDA Fast Track designation for Plinabulin.
Limited to U.S. biotech investors; no broader regional effect.
Low; the news is company‑specific without macro implications.
Counterpoint
The asset sale gain may be overstated; focus on the ongoing operating loss could signal deeper cash concerns.
Key entities
- companyBeyondSpring Inc.
Biopharma company reporting Q3 earnings and clinical updates.
- companyBiolin
Acquirer of BeyondSpring Ltd., supporting the DUBLIN‑4 trial in China.
